サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1672003

幻覚剤APIの世界市場：産業分析・規模・シェア・成長・動向・予測 (2025-2032年)

Psychedelic API Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 167 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
幻覚剤APIの世界市場：産業分析・規模・シェア・成長・動向・予測 (2025-2032年)
出版日: 2025年02月25日
発行: Persistence Market Research
ページ情報: 英文 167 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

主な洞察

  • 幻覚剤APIの市場規模 (2025年)：24億米ドル
  • 市場規模の予測 (2032年)：56億米ドル
  • 世界の市場成長率 (2025～2032年)：CAGR 13.2%

市場促進要因：

世界の幻覚剤APIの市場は、精神疾患の画期的な治療法としての幻覚剤支援療法に対する認識の高まりなど、いくつかの重要な要因によって推進されています。うつ病、不安神経症、PTSDの有病率の上昇が代替治療に対する需要を強め、製薬会社やバイオテクノロジー企業に幻覚剤開発に大規模な投資を行うよう促しています。FDAによるシロシビンやMDMAの画期的治療薬指定などの規制の進展も、市場の拡大をさらに加速させています。幻覚剤化合物の治療可能性を理解することに焦点を当てた臨床試験や共同研究の増加も技術革新と市場成長を促進しています。

市場機会：

幻覚剤APIの市場は、製剤の進歩、メンタルヘルス啓発イニシアチブの拡大、民間および公的部門による投資の増加により、大きな成長機会が示されています。デジタルヘルスプラットフォームとAI主導の創薬技術の統合も、研究能力の向上と次世代の幻覚剤の開発を促進しています。さらに、神経変性疾患、慢性疼痛管理、終末期医療など、メンタルヘルス以外にも幻覚剤の応用の可能性があり、市場範囲が拡大する見通しです。バイオテクノロジー企業、学術機関、政府機関の間の戦略的パートナーシップは、規制状況を乗り切り、幻覚剤に基づく治療法の商業化を加速させる上で極めて重要となるでしょう。

当レポートでは、世界の幻覚剤APIの市場を調査し、市場の定義と概要、市場促進要因・抑制要因、各種動向、市場機会、課題、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲・定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主な動向
  • マクロ経済要因
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値の洞察

  • 薬剤採用分析
  • バリューチェーン分析
  • 主要な取引と合併
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の幻覚剤API市場の展望

  • 主なハイライト
  • 市場規模の分析・予測
  • 世界の幻覚剤API市場の展望：製品タイプ別
  • 世界の幻覚剤API市場の展望：API化合物別
  • 世界の幻覚剤API市場の展望：原料別
  • 世界の幻覚剤API市場の展望：グレード別
  • 世界の幻覚剤API市場の展望：用途別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析
    • 現在の市場規模の分析・予測
    • 市場の魅力分析

第5章 世界の幻覚剤API市場の展望：地域別

  • 主なハイライト
  • 過去の市場規模の分析：地域別
  • 現在の市場規模の分析・予測：地域別
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米の幻覚剤API市場の展望

第7章 欧州の幻覚剤API市場の展望

第8章 東アジアの幻覚剤API市場の展望

第9章 南アジア・オセアニアの幻覚剤API市場の展望

第10章 ラテンアメリカの幻覚剤API市場の展望

第11章 中東・アフリカの幻覚剤API市場の見通し

第12章 競合情勢

  • 市場シェア分析
  • 市場構造
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Core One Labs Inc.
    • Cayman Chemical Company（Matreya）
    • COMPASS Pathways plc
    • Beckley Psytech
    • Atai Life Sciences
    • Tryp Therapeutics
    • Filament Health
    • Ceruvia Lifesciences, LLC
    • BetterLife Pharma
    • Psygen Pharmaceutical
    • Mindset Pharma

第13章 付録

目次
Product Code: PMRREP33267

Persistence Market Research has recently released a comprehensive report on the worldwide market for psychedelic APIs. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global psychedelic API market from 2025 to 2032.

Key Insights:

  • Psychedelic API Market Size (2025E): US$ 2.4 Bn
  • Projected Market Value (2032F): US$ 5.6 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032):13.2%

Psychedelic API Market - Report Scope:

Psychedelic APIs are key components in the development of psychedelic-based therapeutics, which are gaining traction for the treatment of mental health disorders, including depression, PTSD, anxiety, and substance use disorders. These APIs, including psilocybin, LSD, DMT, MDMA, and ketamine, are being extensively studied for their potential to revolutionize psychiatric care. The psychedelic API market caters to pharmaceutical companies, research institutions, and compounding pharmacies, offering high-purity active ingredients for clinical trials and therapeutic applications. Market growth is driven by increasing investment in psychedelic drug research, regulatory shifts supporting medical use, and rising demand for novel mental health treatments.

Market Growth Drivers:

The global psychedelic API market is propelled by several key factors, including growing awareness of psychedelic-assisted therapy as a breakthrough treatment for mental health disorders. The rising prevalence of depression, anxiety, and PTSD has intensified the demand for alternative treatments, prompting pharmaceutical companies and biotech firms to invest heavily in psychedelic drug development. Regulatory advancements, such as the FDA's designation of psilocybin and MDMA as breakthrough therapies, further accelerate market expansion. Additionally, the increasing number of clinical trials and research collaborations focused on understanding the therapeutic potential of psychedelic compounds fosters innovation and market growth.

Market Restraints:

Despite promising growth prospects, the psychedelic API market faces challenges related to regulatory restrictions, ethical concerns, and limited manufacturing capabilities. The classification of many psychedelic substances as Schedule I drugs under global drug control treaties poses significant hurdles for research and commercialization. Additionally, the stigma associated with psychedelics, coupled with varying regulations across different countries, complicates market penetration. High production costs and stringent quality control requirements further limit the availability of pharmaceutical-grade psychedelic APIs, impacting scalability and accessibility.

Market Opportunities:

The psychedelic API market presents significant growth opportunities driven by advancements in drug formulation, the expansion of mental health awareness initiatives, and increasing private and public sector investments. The integration of digital health platforms and AI-driven drug discovery techniques enhances research capabilities and facilitates the development of next-generation psychedelic therapeutics. Moreover, the potential applications of psychedelics beyond mental health, such as in neurodegenerative diseases, chronic pain management, and end-of-life care, expand the market scope. Strategic partnerships between biotech firms, academic institutions, and government bodies will be crucial in navigating regulatory landscapes and accelerating the commercialization of psychedelic-based therapies.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the psychedelic API market globally?
  • Which psychedelic compounds and applications are leading the adoption of psychedelic therapeutics?
  • How are regulatory advancements shaping the competitive landscape of the psychedelic API market?
  • Who are the key players contributing to the psychedelic API market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global psychedelic API market?

Competitive Intelligence and Business Strategy:

Leading players in the global psychedelic API market, including Compass Pathways, MindMed, ATAI Life Sciences, Cybin Inc., and Usona Institute, focus on research innovation, regulatory approvals, and strategic partnerships to gain a competitive edge. These companies are investing in clinical trials, novel drug formulations, and scalable production methods to support the commercialization of psychedelic-based medicines. Collaborations with mental health organizations, research institutions, and policymakers facilitate market entry and accelerate drug development timelines. Additionally, the emphasis on patient advocacy, public education, and regulatory engagement fosters market acceptance and long-term growth in the evolving psychedelic API landscape.

Key Companies Profiled:

  • Compass Pathways
  • MindMed
  • ATAI Life Sciences
  • Cybin Inc.
  • Usona Institute
  • GH Research
  • Beckley Psytech
  • Seelos Therapeutics
  • Small Pharma
  • Tryp Therapeutics

Psychedelic API Market Segmentation

By Product Type

  • API-Grade Psilocybin
  • API-Grade DMT
  • LSD API
  • MDMA API
  • Ketamine API

By API Compound

  • Active Plant Components
  • Novel Synthetic Compounds
  • Metabolites
  • Isotopically Labelled Standards

By Source

  • Natural
  • Synthetic
  • Bio-Synthetic

By Grade

  • GMP
  • Non-GMP

By Application

  • Clinical
  • Research

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Psychedelic API Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overviews

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Drug Adoption Analysis
  • 3.2. Value Chain Analysis
    • 3.2.1. List of Sourcer/Marketplaces
      • 3.2.1.1. Retail
      • 3.2.1.2. E-Commerce
    • 3.2.2. List of Indication (Industry)
  • 3.3. Key Deals and Mergers
  • 3.4. PESTLE Analysis
  • 3.5. Porter's Five Force Analysis

4. Global Psychedelic API Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn ) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn ) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn ) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn ) Analysis and Forecast, 2025-2032
  • 4.3. Global Psychedelic API Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn ) Analysis, By Product Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
      • 4.3.3.1. API-Grade Psilocybin
      • 4.3.3.2. API-Grade DMT
      • 4.3.3.3. LSD API
      • 4.3.3.4. MDMA API
      • 4.3.3.5. Ketamine API
      • 4.3.3.6. Others
    • 4.3.4. Market Attractiveness Analysis: Product Type
  • 4.4. Global Psychedelic API Market Outlook: API Compound
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn ) Analysis, By API Compound, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
      • 4.4.3.1. Active Plant Components
      • 4.4.3.2. Novel Synthetic Compounds
      • 4.4.3.3. Metabolites
      • 4.4.3.4. Isotopically Labelled Standards
    • 4.4.4. Market Attractiveness Analysis: API Compound
  • 4.5. Global Psychedelic API Market Outlook: Source
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn ) Analysis, By Source, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
      • 4.5.3.1. Natural
      • 4.5.3.2. Synthetic
      • 4.5.3.3. Bio-Synthetic
    • 4.5.4. Market Attractiveness Analysis: Source
  • 4.6. Global Psychedelic API Market Outlook: Grade
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn ) Analysis, By Grade, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
      • 4.6.3.1. GMP
      • 4.6.3.2. Non-GMP
    • 4.6.4. Market Attractiveness Analysis: Grade
  • 4.7. Global Psychedelic API Market Outlook: Application
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn ) Analysis, By Application, 2019-2024
    • 4.7.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
      • 4.7.3.1. Clinical
      • 4.7.3.2. Research
    • 4.7.4. Market Attractiveness Analysis: Application

5. Global Psychedelic API Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn ) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Psychedelic API Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product Type
    • 6.2.3. By API Compound
    • 6.2.4. By Source
    • 6.2.5. By Grade
    • 6.2.6. By Application
  • 6.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
    • 6.4.1. API-Grade Psilocybin
    • 6.4.2. API-Grade DMT
    • 6.4.3. LSD API
    • 6.4.4. MDMA API
    • 6.4.5. Ketamine API
    • 6.4.6. Others
  • 6.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
    • 6.5.1. Active Plant Components
    • 6.5.2. Novel Synthetic Compounds
    • 6.5.3. Metabolites
    • 6.5.4. Isotopically Labelled Standards
  • 6.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
    • 6.6.1. Natural
    • 6.6.2. Synthetic
    • 6.6.3. Bio-Synthetic
  • 6.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
    • 6.7.1. GMP
    • 6.7.2. Non-GMP
  • 6.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
    • 6.8.1. Clinical
    • 6.8.2. Research
  • 6.9. Market Attractiveness Analysis

7. Europe Psychedelic API Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product Type
    • 7.2.3. By API Compound
    • 7.2.4. By Source
    • 7.2.5. By Grade
    • 7.2.6. By Application
  • 7.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
    • 7.4.1. API-Grade Psilocybin
    • 7.4.2. API-Grade DMT
    • 7.4.3. LSD API
    • 7.4.4. MDMA API
    • 7.4.5. Ketamine API
    • 7.4.6. Others
  • 7.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
    • 7.5.1. Active Plant Components
    • 7.5.2. Novel Synthetic Compounds
    • 7.5.3. Metabolites
    • 7.5.4. Isotopically Labelled Standards
  • 7.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
    • 7.6.1. Natural
    • 7.6.2. Synthetic
    • 7.6.3. Bio-Synthetic
  • 7.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
    • 7.7.1. GMP
    • 7.7.2. Non-GMP
  • 7.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
    • 7.8.1. Clinical
    • 7.8.2. Research
  • 7.9. Market Attractiveness Analysis

8. East Asia Psychedelic API Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product Type
    • 8.2.3. By API Compound
    • 8.2.4. By Source
    • 8.2.5. By Grade
    • 8.2.6. By Application
  • 8.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
    • 8.4.1. API-Grade Psilocybin
    • 8.4.2. API-Grade DMT
    • 8.4.3. LSD API
    • 8.4.4. MDMA API
    • 8.4.5. Ketamine API
    • 8.4.6. Others
  • 8.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
    • 8.5.1. Active Plant Components
    • 8.5.2. Novel Synthetic Compounds
    • 8.5.3. Metabolites
    • 8.5.4. Isotopically Labelled Standards
  • 8.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
    • 8.6.1. Natural
    • 8.6.2. Synthetic
    • 8.6.3. Bio-Synthetic
  • 8.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
    • 8.7.1. GMP
    • 8.7.2. Non-GMP
  • 8.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
    • 8.8.1. Clinical
    • 8.8.2. Research
  • 8.9. Market Attractiveness Analysis

9. South Asia and Oceania Psychedelic API Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product Type
    • 9.2.3. By API Compound
    • 9.2.4. By Source
    • 9.2.5. By Grade
    • 9.2.6. By Application
  • 9.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
    • 9.4.1. API-Grade Psilocybin
    • 9.4.2. API-Grade DMT
    • 9.4.3. LSD API
    • 9.4.4. MDMA API
    • 9.4.5. Ketamine API
    • 9.4.6. Others
  • 9.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
    • 9.5.1. Active Plant Components
    • 9.5.2. Novel Synthetic Compounds
    • 9.5.3. Metabolites
    • 9.5.4. Isotopically Labelled Standards
  • 9.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
    • 9.6.1. Natural
    • 9.6.2. Synthetic
    • 9.6.3. Bio-Synthetic
  • 9.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
    • 9.7.1. GMP
    • 9.7.2. Non-GMP
  • 9.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
    • 9.8.1. Clinical
    • 9.8.2. Research
  • 9.9. Market Attractiveness Analysis

10. Latin America Psychedelic API Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product Type
    • 10.2.3. By API Compound
    • 10.2.4. By Source
    • 10.2.5. By Grade
    • 10.2.6. By Application
  • 10.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
    • 10.4.1. API-Grade Psilocybin
    • 10.4.2. API-Grade DMT
    • 10.4.3. LSD API
    • 10.4.4. MDMA API
    • 10.4.5. Ketamine API
    • 10.4.6. Others
  • 10.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
    • 10.5.1. Active Plant Components
    • 10.5.2. Novel Synthetic Compounds
    • 10.5.3. Metabolites
    • 10.5.4. Isotopically Labelled Standards
  • 10.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
    • 10.6.1. Natural
    • 10.6.2. Synthetic
    • 10.6.3. Bio-Synthetic
  • 10.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
    • 10.7.1. GMP
    • 10.7.2. Non-GMP
  • 10.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
    • 10.8.1. Clinical
    • 10.8.2. Research
  • 10.9. Market Attractiveness Analysis

11. Middle East & Africa Psychedelic API Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product Type
    • 11.2.3. By API Compound
    • 11.2.4. By Source
    • 11.2.5. By Grade
    • 11.2.6. By Application
  • 11.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
    • 11.4.1. API-Grade Psilocybin
    • 11.4.2. API-Grade DMT
    • 11.4.3. LSD API
    • 11.4.4. MDMA API
    • 11.4.5. Ketamine API
    • 11.4.6. Others
  • 11.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
    • 11.5.1. Active Plant Components
    • 11.5.2. Novel Synthetic Compounds
    • 11.5.3. Metabolites
    • 11.5.4. Isotopically Labelled Standards
  • 11.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
    • 11.6.1. Natural
    • 11.6.2. Synthetic
    • 11.6.3. Bio-Synthetic
  • 11.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
    • 11.7.1. GMP
    • 11.7.2. Non-GMP
  • 11.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
    • 11.8.1. Clinical
    • 11.8.2. Research
  • 11.9. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Core One Labs Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Cayman Chemical Company (Matreya)
    • 12.3.3. COMPASS Pathways plc
    • 12.3.4. Beckley Psytech
    • 12.3.5. Atai Life Sciences
    • 12.3.6. Tryp Therapeutics
    • 12.3.7. Filament Health
    • 12.3.8. Ceruvia Lifesciences, LLC
    • 12.3.9. BetterLife Pharma
    • 12.3.10. Psygen Pharmaceutical
    • 12.3.11. Mindset Pharma

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations